- Home
- ACCS vs JSPR Comparison
ACCS vs JSPR Comparison
Compare ACCS & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$9.73
N/A
Current Price
$1.57
Company Overview
Basic Information| Metric | ACCS | JSPR |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 43.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACCS | JSPR |
|---|---|---|
| Price | $9.73 | $1.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $14.00 | ★ $18.13 |
| AVG Volume (30 Days) | 23.7K | ★ 1.0M |
| Earning Date | 11-11-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,646,000.00 | N/A |
| Revenue This Year | $0.18 | N/A |
| Revenue Next Year | $7.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.30 | N/A |
| 52 Week Low | $7.72 | $1.39 |
| 52 Week High | $13.35 | $7.19 |
Technical Indicators
Market Signals| Indicator | ACCS | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 43.43 |
| Support Level | $9.00 | $1.47 |
| Resistance Level | $11.34 | $1.61 |
| Average True Range (ATR) | 0.75 | 0.15 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 26.49 | 24.24 |
Price Performance
Historical Comparison ACCS
JSPR
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.